Single-agent or combination chemotherapy regimens have not impacted the short median survival of patients with metastatic melanoma, and complete or durable responses are rare. Biologic response modifiers (interferon and interleukin-2) have produced durable remissions in a small cohort of patients, and phase II trials of biochemotherapy suggest more benefit.
Methods
The authors retrospectively reviewed the status of the current treatments of metastatic melanoma focusing on biochemotherapy.
Results
Regimens include both sequential and concurrent approaches for inpatient and outpatient treatment settings. Overall response rates in phase II trials are 40% to 60% with complete responses of 10% to 20% and median survivals in the 11- to 12-month range. Modifications of concurrent biochemotherapy regimens have maintained efficacy and reduced toxicity. Small phase III trials suggest a survival advantage of biochemotherapy (P=.05).
Conclusions
Biochemotherapy remains a promising new treatment for metastatic melanoma. A large Intergroup trial E3695 comparing concurrent biochemotherapy to combination chemotherapy alone is powered to answer important survival questions.
References
1.
GreenleeR.T., Hill-HarmonM.B., MurrayT.. Cancer statistics, 2001.CA Cancer J Clin.2001; 51: 15–36.
2.
BalchC.M., SoongS.J., MuradT.M.. A Multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).J Clin Oncol.1983; 1: 126–134.
AhmannD.L., CreaganE.T., HahnR.G.. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma.Cancer.1989; 63: 224–227.
8.
AgarwalaS.S., KirkwoodJ.M.. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.Oncologist.2000; 5: 144–151.
9.
MiddletonM.R., GrobbJ.J., AaronsonN.. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J Clin Oncol.2000; 18: 158–166.
10.
Del PreteS.A., MaurerL.H., O'DonnellJ.. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.Cancer Treat Rep.1984; 68: 1403–1405.
11.
LeghaS.S., RingS., PapadopoulosN.. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.Cancer.1989; 64: 2024–2029.
12.
BuzaidA.C., LeghaS.S., WinnR.. Cisplatin (C), vinblastine (V), dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results phase III cancer community oncology program (CCOP).Proc Annu Meet Am Soc Clin Oncol.1993; 12: 1328. Abstract
13.
ChapmanP.B., EinhornL.H., MeyersM.L.. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.J Clin Oncol.1999; 17: 2745–2751.
14.
RumkeP., KleebergU.R., MacKieR.M.. Tamoxifen as a single agent for advanced melanoma in postmenopausal women: a phase II study of the EORTC Malignant Melanoma Cooperative Group.Melanoma Res.1992; 2: 153–156.
15.
CocconiG., BellaM., CalabresiF.. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.N Engl J Med.1992; 327: 516–523.
16.
McClayE.F., MastrangeloM.J., SprandioJ.D.. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.Cancer.1989; 63: 1291–1295.
17.
McClayE.F., MastrangeloM.J., BerdD.. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials.Int J Cancer.1992; 50: 553–556.
18.
McClayE.F., AlbrightK.D., JonesJ.A.. Modulation of cisplatin resistance in human malignant melanoma cells.Cancer Res.1992; 52: 6790–6796.
19.
McClayE.F., JonesJ.A., WinskiP.J.. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.Cancer Res.1993; 53: 1571–1576.
20.
McClayE.F., JonesJ.A., WinskiP.J.. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.Cancer Res.1996; 56: 3993–3997.
21.
DesaiP.B., BhardwajR., DamleB.. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells.Cancer Chemother Pharmacol.1995; 36: 368–372.
22.
KirkJ., SyedS.K., HarrisA.L.. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.Biochem Pharmacol.1994; 48: 277–285.
23.
CabotM.C., GiulianoA.E., VolnerA.. Tamoxifen retards glycosphingolipid metabolism in human cancer cells.FEBS Lett.1996; 394: 129–131.
24.
FalksonC.I., IbrahimJ., KirkwoodJ.M.. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus decarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study.J Clin Oncol.1998; 16: 1743–1751.
25.
RusthovenJ.J., QuirtI.C., IscoeN.A.. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol.1996; 14: 2083–2090.
26.
O'DayS.J., BoasbergP.D., KristedjaT.S.. High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.Cancer.2001; 92: 609–619.
27.
KirkwoodJ.. Interferons. In: DeVitaVTJr, HellmanS., RosenbergS.A., eds. Cancer: Principles & Practice of Oncology.Philadelphia, PA: Lippincott-Raven;2001: 461–471. Chap 20.
FalksonC.I., FalksonG., FalksonH.C.. Improved results with the addition of interferon alfa-2B to dacarbazine in the treatment of patients with metastatic malignant melanoma.J Clin Oncol.1991; 9: 1403.
30.
KirkwoodJ.M., StrawdermanM.H., ErnstoffM.S.. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol.1996; 14: 7–17.
31.
RosenbergS.A., YangJ.C., TopalianS.L.. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.JAMA.1994; 271: 907–913.
32.
AtkinsM.B., LotzeM.T., DutcherJ.P.. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J Clin Oncol.1999; 17: 2105–2116.
33.
KeilholzU., ConradtC., LeghaS.S.. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.J Clin Oncol.1998; 16: 2921–2929.
34.
AllenI.E., KupelnickB., KumashiroM.. Efficacy of interleukin-2 in the treatment of metastatic melanoma: systematic review and meta-analysis.Cancer Ther.1998; 1: 168–173.
35.
KeilholzU., GoeyS.H., PuntC.J.. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.J Clin Oncol.1997; 15: 2579–2588.
36.
KeilholzU., ScheibenbogenC., TilgenW.. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.Cancer.1993; 72: 607–614.
37.
FlahertyL.E., AtkinsM., SosmanJ.. Randomized phase II trial of chemotherapy and outpatient biotherapy with interleukin-2 (IL-2) and interferon alpha (IFN) in metastatic malignant melanoma (MMM).Proc Annu Meet Am Soc Clin Oncol.1999; 18: 2070. Abstract.
38.
HellstrandK., BruneM., NarediP.. Histamine: a novel approach to cancer immunotherapy.Cancer Invest.2000; 18: 347–355.
39.
AgarwalaS.S., GlaspyJ., O'DayS.J.. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.J Clin Oncol.2002; 20: 125–133.
40.
LeghaS.S., RingS., EtonO.. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma.J Clin Oncol.1998; 16: 1752–1759.
41.
McDermottD.F., MierJ.W., LawrenceD.P.. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2b in patients with metastatic melanoma.Clin Cancer Res.2000; 6: 2201–2208.
42.
O'DayS.J., GammonG., BoasbergP.D.. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.J Clin Oncol.1999; 17: 2752–2761.
43.
ThompsonJ.A., GoldP.J., FeferA.. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.Semin Oncol.1997; 24(1 suppl 4): S44–S48.
44.
FlahertyL.E., AtkinsM., SosmanJ.. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.J Clin Oncol.2001; 19: 3194–202.
45.
KhayatD., BorelC., TouraniJ.M.. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma.J Clin Oncol.1993; 11: 2173–2180.
46.
LeghaS.S., RingS., BedikianA.. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.Ann Oncol.1996; 7: 827–835.
47.
RichardsJ.M., MehtaN., RammingK.. Sequential chemoimmunotherapy in the treatment of metastatic melanoma.J Clin Oncol.1992; 10: 1338–1343.
48.
AtkinsM.B., O'BoyleK.R., SosmanJ.A.. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.J Clin Oncol.1994; 12: 1553–1560.
49.
EtonO., LeghaS., BedikianA.. Phase III randomized trial of cisplatin, vinblastine, and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alfa-2b (INF) versus CVD in patients (pts) with metastatic melanoma.Proc Annu Meet Am Soc Clin Oncol.2000; 19: 2174. Abstract.
50.
O'DayS.J., BoasbergP.D., KristedjaT.. A phase II study of maintenance biotherapy (MBT) with intermittent high dose decrescendo interleukin-2 (IL-2) for patients with metastatic melanoma (MM) responding to concurrent biochemotherapy (CBC).Proc Annu Meet Am Soc Clin Oncol.2000; 19: 2245. Abstract.
51.
KeilholzU., PuntC.J.A., GoreM.. Dacarbazine, cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: Interim analysis of EORTC trial 18951.Proc Annu Meet Am Soc Clin Oncol.1999; 18: 2043. Abstract.
52.
RosenbergS.A., YangJ.C., SchwartzentruberD.J.. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b.J Clin Oncol.1999; 17: 968–975.
